Drug Trial Radar · NCT02933606
Phase II Study of BNC210 in PTSD
Last checked: Nov 19, 2026Latest source record: Feb 27, 2023 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
193
Actual
Start
Jun 30, 2016
Primary completion
Jul 5, 2018
Study completion Jul 25, 2018
Sponsor
- Lead sponsor
- Bionomics LimitedIndustry
- Sponsor type
- Industry
- First posted
- Oct 14, 2016
Design
- Study type
- Interventional
- Phase
- Phase 2
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- Yes
- Who can join
- All sexes, from 18 years, up to 70 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
This is a randomized, double-blind, placebo-controlled study, evaluating the effects of BNC210 versus placebo on the symptoms of Post-Traumatic Stress Disorder, as measured by the Clinician-Administered PTSD Scale for DSM-5 (CAPS-5). The secondary objectives of the study are to evaluate the effects of BNC210 on anxiety, depression, global functioning and patient reported outcomes in patients with PTSD. Safety and tolerability of BNC210 will also be assessed. Study participants will receive 12 weeks of blinded treatment followed by a 3 week follow-up period.
Conditions
- Post-Traumatic Stress Disorder
Interventions
BNC210Drug
PlaceboDrug
Primary outcomes
What the sponsor says the trial is designed to measure.
- Clinician-Administered PTSD Scale for the Diagnostic and Statistical Manual of Mental Disorders, 5th Edition (DSM-5) (CAPS-5), Total Symptom Severity ScoreTime frame: 12 weeks.
Locations
25 sites in 2 countries. Site status is shown where the registry gives one.
Site not named
Oceanside, California
Site not named
Rancho Mirage, California
Site not named
Redlands, California
Site not named
Riverside, California
Site not named
Gainesville, Florida
Site not named
Jacksonville, Florida
Site not named
Lauderhill, Florida
Site not named
North Miami, Florida
Site not named
Oakland Park, Florida
Site not named
Orlando, Florida
Site not named
Hoffman Estates, Illinois
Site not named
Overland Park, Kansas
Site not named
New Bedford, Massachusetts
Site not named
Lincoln, Nebraska
Site not named
Las Vegas, Nevada
Site not named
Berlin, New Jersey
Site not named
Canton, Ohio
Site not named
Memphis, Tennessee
Site not named
Dallas, Texas
Site not named
San Antonio, Texas
Site not named
Penrith, New South Wales, Australia
Site not named
Auchenflower, Queensland, Australia
Site not named
Toowong, Queensland, Australia
Site not named
Elizabeth Vale, South Australia, Australia
Site not named
St Kilda, Victoria, Australia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.